EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Hans Furuland iD, Anders Olof Larsson iD, Milica Uhde, Kristel Parv iD, Matilda Almstedt iD, Thomas Cars iD, Maria K Svensson iD

Journal of Internal Medicine · 2026-08 · 300 (2) · 179-192

DOI: 10.1111/joim.70087 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Internal Medicine, online erschienen am 26.03.2026. Verfasst von Hans Furuland und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Renal Medicine, Uppsala University Hospital, Uppsala, Sweden. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Heart Failure, Hyperkalemia, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hyperkalaemia is a serious complication in patients with chronic kidney disease (CKD) and heart failure (HF), often leading to the discontinuation of renin–angiotensin–aldosterone system inhibitors (RAASi; renin‐angiotensin system inhibitors [RASi] and mineralocorticoid receptor antagonists [MRAs]) despite their cardiorenal benefits. Although potassium binders, especially second‐generation potassium binders, reduce the risk of hyperkalaemia in clinical trials, real‐world evidence on whether they enable RAASi continuation and influence clinical outcomes remains scarce.

Methods

This observational, population‐based cohort study used Swedish healthcare data from the DEMONSTRATE database to identify adults with non‐dialysis (ND) CKD and/or HF who initiated potassium binders (2018–2022). Patients were stratified by potassium binder generation. RASi and MRA treatment changes were assessed at 6 months, and clinical outcomes (all‐cause mortality, hospitalization and three‐point major adverse cardiovascular events [3P‐MACE]) were evaluated over a 3‐year follow‐up using propensity‐score‐weighted Kaplan–Meier analyses.

Results

Of 7913 potassium binder episodes (6232 patients), 7.1% used second‐generation binders. These episodes were associated with increased RAASi persistence at 6 months: 76.9% and 57.5% of second‐generation users maintained RASi and MRA therapy, respectively, compared with 66.4% and 47.8% in the first‐generation group. Patients who maintained RASi had lower observed all‐cause mortality and hospitalization rates, but no difference in incidence of 3P‐MACE was found.

Conclusion

Second‐generation potassium binders were associated with higher RAASi persistence than first‐generation binders. RASi persistence was associated with lower observed rates of all‐cause mortality and hospitalization, with no clear differences in 3P‐MACE. These findings suggest that potassium binders may enable sustained RAASi use in patients with ND‐CKD and/or HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsHeart FailureHyperkalemiaAngiotensin-Converting Enzyme InhibitorsRenal Insufficiency, ChronicPotassiumAngiotensin Receptor AntagonistsHumansFemaleMaleAgedRenin-Angiotensin SystemDatabases, FactualSwedenMiddle AgedHospitalization

Stichwörter der Autor:innen

hyperkalemiamineralocorticoid receptor antagonistspotassium bindersrenin–angiotensin system inhibitorstreatment persistence

Substanzen

Mineralocorticoid Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsPotassiumAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medical Sciences, Renal Medicine, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden.
  • Vifor Pharma Nordiska AB, Solna, Sweden.
  • Sence Research AB, Uppsala, Sweden.
  • Uppsala Clinical Research Center, Uppsala, Sweden.

ORCID-Profile: Hans Furuland, Anders Olof Larsson, Kristel Parv, Matilda Almstedt, Thomas Cars, Maria K Svensson

Zitieren

APA

Furuland, H., Larsson, A. O., Uhde, M., Parv, K., Almstedt, M., Cars, T., & Svensson, M. K. (2026). Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database). Journal of Internal Medicine, 300(2), 179-192. https://doi.org/10.1111/joim.70087

Vancouver

Furuland H, Larsson AO, Uhde M, Parv K, Almstedt M, Cars T, et al. Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database). Journal of Internal Medicine. 2026;300(2):179-192. doi:10.1111/joim.70087

BibTeX
@article{Furuland2026,
  author = {Furuland, Hans and Larsson, Anders Olof and Uhde, Milica and Parv, Kristel and Almstedt, Matilda and Cars, Thomas and Svensson, Maria K},
  title = {Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)},
  journal = {Journal of Internal Medicine},
  year = {2026},
  volume = {300},
  number = {2},
  pages = {179--192},
  doi = {10.1111/joim.70087}
}
Kostenlos starten →